A Local Register Study For Major Depression Of Paroxetine Controlled Release
A Local Register Study For Major Depression Of Paroxetine Controlled Release
The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to
 Paroxetine Immediate Release, as well as the drug tolerability profile when treated on
 patients with Major Depression.
Inclusion Criteria:

 -  Patients with Major Depressive Disorder,score on depression rating scale reach a
 specific point(17 item Hamilton Depression Scale>18).

 Exclusion criteria:

 -  patients use monoamine oxidase inhibitors (MAOIs), benzodiazepines, Chinese herbal
 medicines, acupuncture, moxibustion or other psychoactive medications other than
 zolpidem, zopiclone;diagnosed with other Axis I disorder other; not responsive to
 paroxetine therapy before; pregnant or lactating, have serious medical disorder or
 condition that would preclude the administration of paroxetine; have a history of
 seizure disorders (except for febrile seizures in childhood); require treatment with
 warfarin anticoagulants, phenytoin, cimetidine, sumatriptan, type 1C antiarrhythmics,
 quinidine or sulfonylurea derivatives; are substance abuse or dependence (alcohol or
 drugs) within 6 months prior to this trial; have had electroconvulsive therapy within
 2 months of entry into the study; pose a current, serious suicidal or homicidal risk;
 have taken other psychotropic drugs or antidepressants other than MAO inhibitors
 within 7 days of baseline and MAO inhibitors within 14 days of baseline; have taken
 any investigational drug, or participated in a clinical trial within the past 3
 months; are hypersensitivity to paroxetine; have undergoing formal
 psychotherapy/psychoanalysis.